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Coronary Responses and Differential
Mechanisms of Late Stent Thrombosis Attributed to
First-Generation Sirolimus- and Paclitaxel-Eluting Stents
Gaku Nakazawa, MD,* Aloke V. Finn, MD,† Marc Vorpahl, MD,* Elena R. Ladich, MD,*
Frank D. Kolodgie, PHD,* Renu Virmani, MD*
Gaithersburg, Maryland; and Atlanta, Georgia
Objectives The purpose of this study was to assess the mechanism(s) of late stent thrombosis (LST) and vascular healing
responses in first-generation polymeric drug-eluting stents (DES).
Background Recent clinical trials have reported variations in late lumen loss between first-generation sirolimus-eluting stents
(SES) and paclitaxel-eluting stents (PES). Little is known, however, about the vascular responses, time course of
healing, and underlying mechanism(s) of complications of LST between platforms in human coronary implants.
Methods The overall analysis included 174 cases (230 DES lesions) from the CVPath Institute’s stent registry. Histomor-
phometry was performed on coronary stents from 127 patients (171 lesions) who died 30 days after receiving
stent implants in which fibrin deposition, endothelial strut coverage, inflammatory response, and mechanism(s)
of in-stent thrombosis were assessed.
Results Both platforms demonstrated increased neointimal thickness over time where values were greater in PES (mean
0.13 mm; range 0.03 to 0.20 mm) than SES (mean 0.10 mm; range 0.04 to 0.15 mm; p  0.04). The percent-
age of uncovered struts was similar between SES and PES including stents with LST (SES  21% vs. PES 
27%; p  0.47). The underlying mechanism(s) of LST, however, was strikingly different between platforms; local-
ized strut hypersensitivity was exclusive to SES, whereas malapposition secondary to excessive fibrin deposition
was the underlying cause in PES. Moreover, although both PES and SES showed nearly complete strut coverage
after 12 months for on-label use, the majority of stents placed for off-label indications remained unhealed after
12 months in both types of DES.
Conclusions Differential mechanisms of LST involving either hypersensitivity or excessive fibrin were identified between
first-generation DES in which overall stent healing was further delayed in DES placed for off-label indications.
(J Am Coll Cardiol 2011;57:390–8) © 2011 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.05.066i
r
t
t
d
r
(
p
N
l
t
m
t
a
she introduction of drug-eluting stents (DES) has made a
ignificant impact on restenosis rates, as shown in many
andomized trials (1,2) and in autopsy studies (3), thus
roviding an overall benefit to patients by decreasing the
ncidence of target lesion revascularization. One of the main
rawbacks to localized stent-based drug delivery, however,
rom *CVPath Institute, Gaithersburg, Maryland; and the †Emory University School
f Medicine, Atlanta, Georgia. CVPath Institute solely sponsored the work with no
cknowledgment to industry or other resources. CVPath Institute, Inc., has research
rants from the Medtronic Cardiovascular, Abbott Vascular, Terumo Medical
orporation, Atrium Medical, Boston Scientific, and Cordis Johnson & Johnson. Dr.
inn is a consultant for Cordis Johnson & Johnson and Abbott Vascular with
ponsored research grants from Medtronic Cardiovascular and St. Jude Medical. Dr.
irmani is a consultant for Medtronic Cardiovascular, Abbott Vascular, Terumo
edical Corporation, Atrium Medical, WL Gore, Biosensors Intl, GlaxoSmithKline,
nd Lutonix. All other authors have reported that they have no relationships to
isclose.a
Manuscript received March 10, 2010; revised manuscript received May 27, 2010,
ccepted May 31, 2010.s the associated long-term delay in healing (i.e., lack of
e-endothelialization and poor strut coverage) (3), whereby
here is an associated infrequent but real risk of late stent
hrombosis (LST) (4). Although clinical trials support
ifferences in angiographic late lumen loss in patients
eceiving first-generation sirolimus-eluting stents (SES)
Cypher, Cordis Corp., Miami Lakes, Florida) and
aclitaxel-eluting stents (PES) (Taxus, Boston Scientific,
atick, Massachusetts) (5), it remains unclear whether
ong-term histologic responses between them exist and how
his relates to the time course of arterial healing and
echanism(s) of LST.
Supportive evidence of delayed arterial healing in response
o coronary DES implants in humans is mostly derived from
utopsy studies in which they are found to exhibit severe
uppression of smooth muscle cell infiltration, persistent fibrin,
nd poor endothelial coverage and the presence of uncovered
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erspective, the pathology data reinforce the importance of
hese attributes as essential to the maintenance of long-term
uminal patency.
The clinical impact of delayed arterial healing becomes
ignificant considering that after initial approvals in 2002,
rst-generation polymer-based DES were implanted in mil-
ions of patients worldwide, and SES and PES still remain
iable contenders in the device market. Therefore, understand-
ng the relevance of histopathologic findings from devices used
n a global practice of medicine is paramount. Along these
ame lines, the drawbacks to first-generation DES used in a
rand-scale clinical setting can provide valuable information,
hich will perhaps improve the management of patients
eceiving current- and next-generation DES in addition to
mproving future stent designs. Moreover, the occurrence of
ST is a real phenomenon and has been described up to 5
ears post-implantation and beyond, where appropriate patient
anagement becomes critical to survival. Known fundamental
ifferences exist between SES and PES including the choice of
rug, release kinetics, polymer, and stent platform.
The present study emphasizes unique mechanisms of
elayed arterial healing and LST in SES and PES deployed
or on- or off-label indications using a registry database of
utopsy cases. The present findings have important clinical
ignificance considering that our data suggest that the
urrent regimen of dual antiplatelet therapy (i.e., 12
onths) after DES implantation may be adequate for the
ast majority of DES placed for on-label indications.
onversely, a significantly higher number of DES im-
lanted for off-label indications remained unhealed after 12
onths, potentially suggesting the importance of extending
he period of dual antiplatelet therapy beyond 12 months in
his setting.
ethods
atients and lesions. Available DES from 174 autopsies
DES for 230 lesions) from the CVPath Institute’s stent
egistry were examined in which 93 of the stented lesions
ere used in previous reports (3,6–8). Of these, 47 patients
total of 59 lesions; SES  25 and PES  34) survived less
han 30 days post-implantation, whereas 127 patients (total
f 171 lesions; SES  77 and PES  94) survived longer
han 30 days. In hearts with multiple stents, overlapping and
onsecutively implanted DES were treated as 1 lesion,
hereas DES showing gaps of 5 mm were considered
eparate lesions, as described previously (6). Clinical histo-
ies and cardiac catheterization reports when available were
eviewed. The cause of death was reported as stent-related
oronary death, nonstent-related cardiac death, or noncar-
iac related, as previously defined (6).
istologic preparation. The hearts were fixed in 10%
eutral-buffered formalin, and the stents were carefully
emoved and radiographs obtained before submitting for
ethylmethacrylate embedding. The entire stent was then fawed consecutively from the
roximal to distal ends at 2- to
-mm intervals along the entire
ength. The sections were pre-
ared at 6 m and stained with
ematoxylin and eosin and mod-
fied Movat pentachrome. De-
ending on the device length, the
umber of histologic sections
vailable for analysis ranged from
sections for 8-mm stents to a
aximum of 15 sections for
onger, 40-mm lengths. Based on this technique, for lesions
ith a stent in place for30 days, an average of 8.81 2.43
truts per section were analyzed for a total number of 7,715
truts in 876 stent cross sections.
orphologic analysis and pathologic assessment. In-
tent coronary thrombi (nonocclusive or occlusive) were
dentified by platelet masses occupying 30% of the cross-
ectional luminal area, whereas restenosis was defined as
75% cross-sectional luminal area narrowing by neointimal
issue. LST, consistent with the clinical definition, was
efined as thrombosis within a stent implanted 30 days
7). Morphometric measurements (IPLab, BD Bioscience
ioimaging, Rockville, Maryland) were performed after
igital image capture and included the external elastic
amina, plaque area, stent area, and lumen area in addition
o the thickness above each strut, as described previously (8).
The severity of fibrin and inflammation was scored
ased on a grading scale of 0 to 4, as described previously
3). The number of stent struts associated with giant cells
nd the maximum number of eosinophils around each
trut were also assessed. Uncovered struts were identified
y an absence of overlying tissue except for thrombus
onsisting of platelets/fibrin; the ratio of uncovered-to-
otal stent struts per section was calculated as described
reviously (6). In select cases, Luna’s method (9) was
sed to confirm the presence of eosinophils, whereas T
ymphocytes were recognized by immunostaining with an
ntibody directed against CD45RO.
The incidence of unhealed stents was determined for
oronary implants distinguished by those in place for 12
nd 12 months. The cutoff was selected based on the
merican Heart Association and the American College of
ardiology recommended duration of dual antiplatelet ther-
py after DES (10). The total number of stent struts per
ection was counted, and the number of uncovered struts
ere summed for each consecutive section and reported as a
ercentage (total number of struts per section). An unhealed
tent was defined by a 30% ratio of uncovered-to-total
tent struts per cross section, as described previously (6), in
hich uncovered struts were recognized by the lack of
eointimal growth involving smooth muscle cells and/or
urface endothelium. A threshold for variations in the ratio of
ncovered-to-total stent struts per cross section was derived
Abbreviations
and Acronyms
BMS  bare-metal stent(s)
DES  drug-eluting stent(s)
LST  late stent
thrombosis
PES  paclitaxel-eluting
stent(s)
SES  sirolimus-eluting
stent(s)rom receiver-operating characteristic curve analysis by equat-
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Mechanism(s) of Late Stent Thrombosis in DES January 25, 2011:390–8ng sensitivity (75%) and specificity (76%) levels near maxi-
um achievable diagnostic accuracy (79%), as reported previ-
usly (6).
Stent comparisons were further performed based on
linical on-label or off-label indications, as summarized in
able 1. Coronary stents indicated for the treatment of de
ovo native lesions of lengths 30 mm were considered as
n-label use, whereas stents deployed for acute myocardial
nfarction or bifurcation lesions, left main artery, bypass
raft, restenosis, chronic total occlusion, or lesion lengths
30 mm were listed as off-label, as defined previously (11).
tatistical analysis. Continuous variables with normal dis-
ribution are expressed as mean  SD. The normality of
istribution was tested with the Wilk-Shapiro test. Com-
arison between patients with SES and PES was examined
y Student t test for continuous variables with a normal
istribution, whereas categorical variables were analyzed by
he Fisher exact test. A Wilcoxon rank-sum test was used
or comparisons of non-normally distributed data, which
ere expressed as median and interquartile range. Statistical
omparisons among DES with varying implant durations
ere performed by a Kruskal-Wallis test followed by post
oc analysis using a Wilcoxon rank-sum test to assess
ignificant differences. A value of p  0.05 was considered
tatistically significant.
esults
atients with DES implants surviving <30 days. Patient
haracteristics such as age, sex, and risk factors for coronary
rtery disease were similar between those receiving SES (19
atients) and PES (28 patients) who died 30 days after
tent placement (Table 2). The number of stents per patient
nd cause of death were also similar between stent types.
nalysis of individual lesions with an implant duration of
30 days (SES  25 days and PES  34 days) for the time
f implantation, indication for stent placement, stent
ength, lesion location, and prevalence of overlapping stents
ere comparable between groups. The incidence of early
tent thrombosis was equivalent for lesions with SES (44%)
Summary of DES Deployed for On- and Off-Labelfor Survivors <30- and >30-Day DurationTable 1 Summ ry of DES Deployed for On- afor Survivors <30- and >30-Day Du
Indication
Total No. of
Lesions
On-label (de novo lesions, 30 mm) 94
Off-label 136
Acute myocardial infarction 74
Long stent (30 mm) 28
Bifurcating lesions 13
Bypass grafts 13
Left main lesions 8
*Lesions in parentheses also had acute myocardial infarction, but occ
DES  drug-eluting stent(s); PES  paclitaxel-eluting stent(s); SES nd PES (38%) (p  0.79). Histologically, no differences in
N
ohe extent of inflammation and fibrin deposition were noted
etween SES and PES implants at 30 days.
atients with DES implants surviving >30 days. Patient
haracteristics such as age, sex, and risk factors for coronary
rtery disease for stent implants with a duration of30 days
ere similar between SES (61 patients) and PES (66
atients) (Table 3). The cause of death was also similar
etween groups, with 30% of patients dying of stent-related
auses. In the lesion-based analysis (SES  77 lesions and
ES  94 lesions), stent duration, indication for stenting,
ationsff-Label Indications
<30-Day Duration >30-Day Duration
SES PES SES PES
8 8 37 41
17 26 40 53
8 (5)* 18 (5)* 23 (2)* 25 (4)*
5 1 11 11
1 1 4 7
1 3 1 8
2 3 1 2†
at bifurcation sites. †One patient had acute myocardial infarction.
mus-eluting stent(s).
atient and Lesion Characteristicsf Survivors W th DES (<30 Days)Table 2 Patient and Lesion Characteristicsof Survivors With DES (<30 Days)
Patient SES PES p Value
Patients, n 19 28
Age, yrs 63 12 66 14 0.47
Male sex 14 (74) 20 (71) 0.99
Hypertension 13/16 (81) 17/24 (71) 0.71
Diabetes 6/16 (38) 8/24 (33) 0.99
Hyperlipidemia 13/16 (81) 13/24 (54) 0.10
Previous MI 8/17 (47) 11/22 (50) 0.99
Previous CABG 3/19 (16) 6/28 (21) 0.72
Aspirin 13/15 (87) 13/17 (76) 0.66
Clopidogrel 12/15 (80) 14/17 (82) 0.99
Stents per patient 1.8 0.7 1.9 1.0 0.64
Cause of death
SRD/NSRCD/NCD 13/6/0 12/11/5 0.08
Lesions, n 25 34
Duration, days 2 (1–7) 6 (3–10) 0.06
Indication for stenting
Stable/ACS/AMI/others 10/5/8/2 13/2/18/0 0.06
Lesion location
LM/LAD/LCX/RCA/graft 2/13/6/3/1 3/14/7/7/3 0.80
Stent length, mm 25.0 (17.5–35.0) 20.5 (16.0–31.8) 0.60
Overlapping 9 (36) 11 (20) 0.79
Stent outcome
Thrombosis 11 (44) 13 (38) 0.79
alues are expressed as mean  SD, n (%), or median (interquartile range) unless otherwise
pecified.
ACS  acute coronary syndrome; AMI  acute myocardial infarction; CABG  coronary artery
ypass graft; CTO  chronic total occlusion; LAD  left anterior descending artery; LCX  left
ircumflex artery; LM  left main artery; MI  myocardial infarction; NCD  noncardiac death;Indicnd O
rationSRCD nonstent-related cardiac death; RCA right coronary artery; SRD stent-related death;
ther abbreviations as in Table 1.
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January 25, 2011:390–8 Mechanism(s) of Late Stent Thrombosis in DEStent length, lesion location, and prevalence of overlapping
tents were comparable in those with DES (Table 3). Of
he total 171 lesions, 93 (54%) were treated for off-label
ndications (SES, 40 of 77 [52%]; PES, 53 of 94 [56%];
 0.64). The incidence of LST was similar among
atients with DES and was observed in 21% of SES
ompared with 27% of PES (p  0.47). Chronic total
cclusion of the stent with organized thrombus was also
qually observed in both SES and PES (6% each; p 0.99).
inally, restenosis was documented in 8% of SES and 5% of
ES lesions (p  0.55).
orphometric analysis and pathologic responses to DES
n patients surviving >30 days. Although external elastic
amina stents and plaque areas were compared between
esions with SES and PES, the mean and maximum
eointimal thicknesses were significantly greater in PES
mean 0.13 mm; range 0.07 to 0.20 mm and maximum 0.23
m; range 0.13 to 0.37 mm) than SES (mean 0.10 mm;
ange 0.04 to 0.15 mm; p  0.04 and maximum 0.17 mm;
ange 0.06 to 0.28 mm; p  0.04) (Table 4). The hetero-
eneity in neointimal thickness between sections (neointi-
al thickness variation in Table 4) was also significantly
reater for PES (0.14 mm; range 0.08 to 0.31 mm) versus
ES (0.10 mm; range 0.03 to 0.22 mm; p  0.02).
oreover, there was a progressive and significant increase in
eointimal thickness beyond 9 and 18 months in lesions
Patient and Lesion Characteristics of SurvivorsTable 3 Patient and Lesion Characteristics
Patient SES
Patients, n 61
Age, yrs 59 1
Male sex 47 (77
Hypertension 31/44 (7
Diabetes 10/45 (2
Hyperlipidemia 31/44 (7
Previous MI 24/51 (4
Previous CABG 8/61 (1
Aspirin 21/30 (7
Clopidogrel 21/31 (6
Stents per patient 1.8 1
Cause of death
SRD/NSRCD/NCD/explant 19/17/2
Lesions, n 77
Duration, days 361 (120–
Indication for stenting
Stable/ACS/AMI /others 39/9/21
Lesion location
LM/LAD/LCX/RCA/graft 1/29/20/
Stent length, mm 22.0 (16.0–
Overlapping 24 (31
Stent outcome
Thrombosis 16 (21
CTO 5 (6)
Restenosis 6 (8)
Values are expressed as mean  SD, n (%), or median (interquartile r
Abbreviations as in Tables 1 and 2.ith PES without evidence of LST (Fig. 1A); although dimilar trends were observed for SES, findings were of
orderline significance (Fig. 1A).
Accumulated fibrin was significantly greater in PES
ompared with SES (fibrin score: PES 1.8; range 1.0 to 2.5
s. SES 0.8; range 0.0 to 2.0; p  0.001) (Table 4). On the
ontrary, SES implants were associated with a significantly
reater inflammatory score compared with PES (SES 1.3;
ange 0.5 to 2.0 vs. PES 1.0; range 0.5 to 1.5; p  0.007).
he contributing cells resulting in greater inflammation
bserved with SES were predominantly eosinophils, lym-
hocytes, and giant cells, and although the incidence of
alapposition was comparable in SES and PES, the under-
ying mechanism is likely related to excessive inflammation
or SES as opposed to persistent fibrin in the case of PES.
The overall incidence of uncovered struts was similar
etween devices, and both were associated with a decreased
requency of unhealed stents beyond 12 months (Fig. 1B).
further analysis revealed nearly complete healing in
tents placed for on-label indications with implant dura-
ions of 12 months, whereas the majority of DES with
ff-label use remained unhealed beyond this similar time
oint (Fig. 1B).
echanism(s) of stent thrombosis by DES. Underlying
athologic causes of in-stent thrombosis were determined
y histologic review (Table 5). There were no significant
DES (>30 Days)rvivors With DES (>30 Days)
PES p Value
66
60 12 0.75
51 (77) 0.99
41/50 (82) 0.23
15/50 (30) 0.49
31/50 (62) 0.51
32/57 (26) 0.44
11/66 (17) 0.63
29/40 (73) 0.99
26/39 (67) 0.99
2.0 1.2 0.36
22/22/17/5 0.75
94
211 (118–383) 0.14
60/4/21/9 0.30
3/40/21/23/7 0.17
21.5 (16.0–30.0) 0.73
27 (29) 0.74
25 (27) 0.47
6 (6) 0.99
5 (5) 0.55
nless otherwise specified.Withof Su
3
)
0)
2)
0)
7)
3)
0)
8)
.2
1/4
570)
/8
26/1
29.5)
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Mechanism(s) of Late Stent Thrombosis in DES January 25, 2011:390–8osis (i.e., 30 days) between SES and PES. Significant
ifferences, however, were found for the underlying tissue
eactions associated with LST for DES implanted for
30 days. For SES, the incidence of LST was signifi-
antly associated with localized hypersensitivity consist-
Morphometric Analysis of DES (>30 Days)Table 4 Morphometric Analysis of DES (>30
SES (n 
External elastic lamina, mm2 14.5
Stent area, mm2 6.8
Plaque area, mm2 7.7
Mean neointimal thickness, mm* 0.10 (0
Maximum neointimal thickness, mm* 0.17 (0
Neointimal thickness variation,† mm* 0.10 (0
Inflammatory score* 1.3 (0
Fibrin score* 0.8 (0
Struts with fibrin, %* 25 (1
Maximum no. of eosinophils per strut 9.1
Struts with giant cells, %* 21 (1
Uncovered struts, %* 21 (1
Incidence of malapposition, n (%) 11 (1
*Expressed as median (interquartile range). †Neointimal thickness
neointimal thickness).
Abbreviations as in Table 1.
Figure 1 Maximal Neointimal Thickness and Prevalence of Unh
in First-Generation SES and PES Stratified by Implant
(A) Bar chart for maximum neointimal thickness in sirolimus-eluting stents (SES) a
maximum neointimal thickness beyond 9 months with further increase after 18 mo
with a gradual increase in neointimal thickness. *Statistically different from the 
stents in SES and PES stratified by duration of the implant (12 or 12 months).
deployed for 12 months. Notably, however, a significant decrease in incidence o
the majority of those with off-label indications remained unhealed beyond 12 mon
months overall and on-label indications. Lesions 30 days were excluded from thng of eosinophils, lymphocytes, and giant cells through-
ut the stented segment (p  0.0005) relative to PES,
hereas the latter was attributed to malapposition sec-
ndary to excessive fibrin deposition on the abluminal
urface of the stent (p  0.03).
s)
sions) PES (n  94 Lesions) p Value
14.0 5.3 0.49
7.2 3.1 0.47
6.8 3.1 0.09
15) 0.13 (0.07–0.20) 0.04
28) 0.23 (0.13–0.37) 0.04
22) 0.14 (0.08–0.31) 0.02
) 1.0 (0.5–1.5) 0.007
) 1.8 (1.0–2.5) 0.001
50 (36–69) 0.0003
1.0 1.7 0.0001
3 (0–9) 0.0001
20 (8–49) 0.72
18 (19) 0.40
n is calculated by (maximum neointimal thickness)  (minimum
Struts
tion
clitaxel-eluting stents (PES) without thrombosis. There is a significant increase in
in PES, whereas a similar but borderline significant trend was observed in SES
9 months category. (B) Bar chart demonstrating the incidence of unhealed
ll, both DES are associated with decreased incidence of unhealed stents
aled stents was only observed in DES placed for on-label indications, whereas
atistical significance: *Statistically significant p  0.05 12 months vs. 12
sis.Day
77 Le
 4.8
 2.1
 3.7
.04–0.
.06–0.
.03–0.
.5–2.0
.0–2.0
0–59)
16.8
1–41)
–54)
4)
variatioealed
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January 25, 2011:390–8 Mechanism(s) of Late Stent Thrombosis in DESLocalized hypersensitivity was documented in 5 cases
nvolving 7 lesions treated by SES in which LST developed
Table 6, Fig. 2A). The patient mean age was 52 years
range 40 to 62 years), and the mean stent length was 27
m (range 18 to 41 mm). The majority of patients receiving
ES died in the very late phase (1 year) in which the mean
mplant duration was 649 days (range 112 to 990 days).
alapposition was observed in 5 lesions (71%) with a mean
ection of struts from the vessel wall of 944 m (range 320
o 1,620 m). Consistently, histologic sections of SES with
ST showed severe inflammation consisting of eosinophils,
nderlying Causes ofhrombosis in Fir t-Generation DESTable 5 Und rlying C uses ofThrombosis in First-Generation DES
SES PES p Value
Early thrombosis (30 days), n 11* 13*
AMI, penetration/prolapse of necrotic core 1 5 0.17
Bifurcation 3 2 0.63
Long/overlapping stents 1 0 0.46
Medial rupture/dissection 3 4 1.00
Malapposition 0 1 1.00
Others† 3 1 0.30
Late thrombosis (30 days), n 16* 25*
AMI, penetration of necrotic core 5 5 0.47
Bifurcation 1 9 0.06‡
Long/overlapping stents 0 2 0.50
Underexpansion 1 1 1.00
Isolated uncovered struts 2 1 0.55
Localized hypersensitivity reaction 7 0 0.0005‡
Malapposition from excessive to fibrin 0 7 0.03‡
Number of lesions with SES or PES. †Includes septic thrombi, stent fracture, and unknown.
Statistical significance by the Fisher exact test.
Abbreviations as in Tables 1 and 2.
irst-Generation DES With Localized Hypersensitivity and MalapposTable 6 First-Generation DES With Localized Hypersensitivity a
Patient #
Age (yrs)/
Sex Lesion
Stent
Type
Total Sten
Segmen
(mm)
SES with localized hypersensitivity
reaction
1 61/M RCA SES 18
2* 40/F LAD SES 27
RCA SES 25
3 49/M LCX SES 2 27
4 46/M LAD SES 23
RCA SES 2 30
5 62/F LAD SES  3 41
PES with malapposition secondary
to excessive fibrin deposition
6* 69/M SV-OM PES 2 33
7 52/M LAD PES 16
8 58/M RCA PES 2 24
9 37/M RCA PES 2 44
10 41/M LCX PES 2 45
11* 48/M LAD PES 24
LCX PES 2 16Presented as Figure 2. †Underlying plaque was not intact in the sample; therefore, malapposition was n
SAP  stable angina pectoris; SV-OM  saphenous vein-obtuse marginal; UAP  unstable angina pecymphocytes, and giant cells throughout the entire stented
egment; however, granulomatous inflammation was only
ocalized to a few stent struts. In most SES with severe
nflammation, there was positive remodeling of the vessel
esulting in a malapposition.
In contrast, the primary contributor to LST in PES
mplants was malapposition secondary to excessive strut
brin, as observed in 7 lesions in 6 patients (Table 6,
ig. 2B) with a mean age of 51 years (range 37 to 69
ears). The mean stent length was 29 mm (range 16 to 45
m), and the mean implant duration was 611 days (range
5 to 1,200 days). The mean distance separating the
truts from the vessel wall was 404 m (range 180 to 620
m). The luminal surface generally lacked endothelial
ell coverage as well as evidence of granulation tissue
onsisting of macrophages, smooth muscle cells, or pro-
eoglycan matrix (Fig. 2B).
iscussion
espite delayed arterial healing and a similar incidence of
ST in first-generation coronary DES obtained at autopsy,
he underlying composition of the neointima associated
ith SES and PES implants is clearly distinct. In patients
ith SES, there was greater inflammation involving eosin-
phils, lymphocytes, and giant cells (hypersensitivity reac-
ion) resulting in positive remodeling and malapposition. In
ontrast, excessive para-strut fibrin and malapposition was
ssociated with PES implants. Intuitively, these findings
upport distinct mechanisms of LST, coinciding with very
iverse stent platforms.
Secondary to Excessive Fibrinalapposition Secondary to Excessive Fibrin
Duration of
Implants
(Months)
Indication for
Implants
Clinical
Presentation Malapposition
Malapposed
Distance
(m)
4 SAP Sudden death No —
17 AMI Sudden death Yes 650
17 AMI Yes 320
18 UAP AMI Yes 1,620
31 SAP AMI Yes 930
31 AMI Yes 1,200
36 SAP Repeat occlusion NA† —
3 SAP Sudden death Yes 650
6 SAP Sudden death Yes 260
7 AMI Sudden death Yes 180
9 SAP Sudden death Yes 450
38 UAP Sudden death Yes 310
40 SAP Sudden death Yes 420
40 AMI Yes 590itionnd M
ted
tot assessed.
toris; other abbreviations as in Tables 1 and 2.
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reater neointimal suppression compared with PES; how-
ver, both DES were associated with increased neointimal
rowth with time, so-called late catch-up. The prevalence of
nhealed stents in patients surviving 12 months was
ifferent based on the indication for placement as nearly
omplete healing was largely confirmed for on-label use,
hereas a significant number of stents (irrespective of the
latform) deployed for off-label indications essentially re-
ained unhealed.
As previously reported, mechanism(s) of LST are likely
ultifactorial (3). Although there is a certain commonality
n the mechanism of LST for both SES and PES in that all
atients demonstrated poor endothelialization, our findings
ndicate the final stimulus for thrombus development may
Figure 2 Representative Images of Late Stent Thrombosis in Fi
(A) Histologic sections from sirolimus-eluting stents (SES). A 40-year-old woman w
(RCA) 17 months antemortem died suddenly 4 days after surgical removal of a me
dogrel) was discontinued 5 days before the surgery. Histologic sections of the SES
ous inflammatory cells were observed within the neointimal area (b). Inflammatory
(Luna stain). Note that the same reaction was observed in the SES in RCA (e) and
tions from a paclitaxel-eluting stent (PES) showing malapposition. A 69-year-old ma
placement (Patient #6 in Table 6). Histologic sections showed thrombotic occlusio
A 48-year-old man with a PES implant in the proximal LAD died suddenly at 40 mo
PES (d). Most struts are malapposed with fibrin deposition underneath the stent se different based on DES type. The disparities in vascular pesponses observed in the present study regarding the stent
ilieu are reminiscent of preclinical models and are un-
oubtedly attributable to differences in the drug load,
olymer coating, and unique elution profile of each device.
Only mild inflammation was exhibited by SES in patients
ith short-term survival; however, with longer implant
urations, inflammation became more prevalent as the
ajority of hypersensitivity cases were documented in de-
ices 1 year old (Table 4). The findings are remarkably
onsistent with preclinical DES implants in porcine coro-
ary arteries, which typically show escalating amounts of
nflammation over time (12). In SES implants in humans,
he inflammatory infiltrate is composed predominantly of
osinophils, multinuclear giant cells, and lymphocytes,
hich leads to positive remodeling, malapposition, and
eneration SES and Strut Malapposition in PES
eived 2 SES in the left anterior descending artery (LAD) and right coronary artery
a (wide excision) (Patient #2 in Table 6). Antiplatelet therapy (aspirin and clopi-
e LAD showed total thrombotic occlusion and diffuse inflammation (a). Numer-
on predominantly consists of T lymphocytes (c) (CD45RO) and eosinophils (d)
re inflammation resulted in malapposition of stent struts (f). (B) Histologic sec-
received a PES in a saphenous vein graft died suddenly 3 months after stent
e PES (a, b); note the malapposition secondary to severe fibrin deposition (c).
atient #11 in Table 6). Histologic sections showed thrombotic occlusion of the
e, f). Thr  thrombus.rst-G
ho rec
lanom
in th
reacti
seve
n who
n in th
nths (P
truts (otentially LST. In our cases, multiple SES implanted in
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January 25, 2011:390–8 Mechanism(s) of Late Stent Thrombosis in DEShe same patient invariably demonstrated these findings
rrespective of location, suggesting the existence of a local-
zed immunologic reaction. As previously postulated (13),
he hypersensitivity reaction is likely attributed to the
olymer rather than drug, which is presumably completely
luted by 3 months.
Our finding that greater fibrin accumulated around struts
n PES also remains consistent with the vascular responses
een in previous preclinical studies. For example, Farb et al.
14) showed a dose-dependent increase in fibrin deposition
nd medial necrosis after deployment of PES in rabbit iliac
rteries, and similar dose escalatory findings were reported
n a porcine model (15). Therefore, we believe that pacli-
axel itself is responsible for excessive fibrin deposition.
Despite a marked difference in neointimal composition
etween DES platforms, all implants exhibiting LST were
ssociated with positive vessel remodeling and, in the
ajority, stent malapposition. The reported occurrence of
ate acquired stent malapposition after DES implantation
xists in approximately 10% of lesions (16,17). Cook et al.
18) reported that stent malapposition was more frequent in
atients with LST (77%) than without (12%). Recent
eta-analysis data also support the finding of late stent
alapposition as significantly higher in DES compared
ith bare metal stents (BMS) (19) and was associated with
ST. In the present study, the overall incidence of malap-
osition was similar between SES and PES. Accordingly,
owever, the underlying mechanisms of this phenomenon
re fundamentally different between platforms.
In the present study, early stent thrombosis and LST
ere equally observed in SES and PES, which is consistent
ith the clinical experience (20,21). Although PES are
ssociated with greater neointimal formation, the incidence
f uncovered struts, the most powerful predictor of risk of
ST, was similar between DES. This, however, was asso-
iated with greater heterogeneity in the healing response to
ES relative to SES, as evidenced by greater disparities in
eointimal thickness. Because histologic sections of PES
emonstrating the thinnest neointima are typically accom-
anied by persistent fibrin, the heterogeneity of arterial
ealing may result from an uneven distribution of drug and
olymer. Further support for variations in available pacli-
axel in a single stent comes from scanning electron micros-
opy studies demonstrating webbing and delamination of
olymer, which is a frequent finding in PES (22). Finally,
ngioscopy studies by Takano et al. (23) also demonstrate
eterogeneity of stent strut coverage in PES compared with
ES.
The gradual increase in neointimal thickness over time
or both first-generation platforms reinforces the notion
hat the arterial responses to DES is a dynamic process
asting well beyond the 6- to 8-month time point recom-
ended for angiographic follow-up in clinical trials. This
ime course of arterial healing contrasts with the pattern of
eointimal formation after BMS placement, which typically
eaks at 6 to 12 months with regression thereafter (24,25). rlinical studies of DES also report a gradual increase in
arget lesion revascularization and neointimal volume by
ntravascular ultrasound occurring over 4 years (26-29).
Although slow to develop, progressive neointimal growth
n DES is likely related to persistent fibrin and inflamma-
ion. In both DES platforms, biological signs of a drug
ffect such as fibrin remain beyond the reported durations of
rug release. Fibrin degradation products, in particular
brin fragment E, are a known initiator of smooth muscle
ell migration and proliferation (30,31), a phase that gen-
rally occurs early after BMS placement. In addition to
brin, the presence of inflammation is yet another plausible
xplanation for the late increases in neointimal formation
ssociated with DES. Nonerodible polymers used in first-
eneration DES, namely, poly(styrene-b-isobutylene-b-
tyrene) for PES and polyethylene-covinyl acetate, and poly
-butyl methacrylate for SES are associated with chronic
nflammation and, in particular for the latter, eosinophils
3,13,22,32) in which the release of various growth factors
s a result of inflammation might serve to promote smooth
uscle cell proliferation (33). In a previous study of human
oronary stents from our laboratory, greater intimal inflam-
ation was found to be an independent predictor of
estenosis (34). Although a dramatic late catch-up in reste-
osis has not been reported in DES, target vessel revascu-
arization rates do increase with time, which is consistent
ith the gradual growth of neointima seen in the present
tudy (Fig. 1A). Therefore, the possibility exists that late
estenosis may erode into the benefit of DES compared with
MS. Consistent with the gradual increase in neointima
ormation over time, it was also found that arterial healing
n both DES platforms was continuous over long periods.
espite the decreased prevalence of unhealed stents (de-
ned as 30% uncovered struts) for implants in place for
12 months, the finding of unhealed struts was heavily
ontingent on the clinical indication for stent placement
egarding on- versus off-label use. In our series, better
utcomes regarding stent healing were found with DES
eployed for on-label indications (demonstrating nearly
omplete healing after 12 months) compared with off-label
se, although strut coverage was still numerically greater in
ff-label DES implanted for 12 months. These findings
ay have implications for the duration of antiplatelet
herapy after DES placement. Our data suggest that for the
ast majority of DES placed in the context of on-label, the
urrent (i.e., 12-month) regimen of dual antiplatelet therapy
or DES implants may be adequate. It is also noteworthy
hat a considerably higher number of DES deployed for
ff-label indications remained unhealed beyond 12 months,
nd, therefore, continued dual antiplatelet therapy for these
atients is advisable.
tudy limitations. Although the pathologic finding of
tents at autopsy might not entirely represent those de-
loyed in survivors, the large number of cases in our registry,
owever, should allow us to provide a more detailed and
eliable assessment of histopathologic findings representa-
t
d
c
t
a
m
C
T
a
s
t
a
fi

i
e
R
P
E
R
1
1
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2
3
3
3
3
3
K
398 Nakazawa et al. JACC Vol. 57, No. 4, 2011
Mechanism(s) of Late Stent Thrombosis in DES January 25, 2011:390–8ive of the general population. Despite the fact that clinical
ata such as antiplatelet therapy were not available in all
ases, the aim of the current study was to investigate the
ime course and differences in arterial healing between SES
nd PES; therefore, the absence of complete clinical infor-
ation does not preclude our assessment.
onclusions
he present data suggest that DES exhibit divergent mech-
nisms of LST in which hypersensitivity likely plays a
ignificant role in SES, whereas for PES, the etiology seems
o be an association with excessive fibrin deposition on the
bluminal surface with malapposition. Another important
nding was the nearly complete healing in DES placed for
12 months with confirmed on-label use, whereas off-label
ndications for both stents resulted in incomplete healing,
ven in DES in place for 12 months.
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